Home | About | Journals | Submit | Contact Us | Français |

**|**HHS Author Manuscripts**|**PMC2860045

Formats

Article sections

Authors

Related links

Sex Transm Dis. Author manuscript; available in PMC 2011 May 1.

Published in final edited form as:

PMCID: PMC2860045

NIHMSID: NIHMS172132

Ramzi A. Alsallaq, PhD,^{1} Joshua T. Schiffer, MD, MSc,^{1,}^{3} Ira M. Longini, Jr., PhD,^{1,}^{4} Anna Wald, MD, MPH,^{5,}^{6,}^{7,}^{8} Lawrence Corey, MD,^{2} and Laith J. Abu-Raddad, PhD^{1,}^{9,}^{10}

Corresponding author: Ramzi A. Alsallaq, 1100 Fairview ave N, M2-C200, P.O. Box 19024, Seattle, WA 98109, USA, Email: ralsalla/at/scharp.org, Tel: +1(206)6676176, Fax:+1(206)6674378

The publisher's final edited version of this article is available at Sex Transm Dis

See other articles in PMC that cite the published article.

The continuation of developing HSV-2 prophylactic vaccines requires parallel mathematical modeling to quantify the impact on the population of these vaccines.

Using mathematical modeling we derived three summary measures for the population impact of imperfect HSV-2 vaccines as a function of their efficacies in reducing susceptibility (*VE _{S}*), genital shedding (

A vaccine with limited efficacy of reducing shedding frequency (*VE _{P}* =10%) and infectivity (

A vaccine with substantially high efficacy of reducing HSV-2 shedding frequency would have a desirable impact at the population level. The vaccine’s short-term impact in a high prevalence setting in Africa would be a substantial decrease in incidence, whereas its immediate impact on prevalence would be small and would increase slowly over time.

Herpes simplex virus type-2 (HSV-2) infection is highly prevalent in sub-Saharan Africa [1–10] and around the globe [11–13]. The broad spread of HSV-2 is further complicated by the common mode of transmission and the synergistic epidemiologic pattern that it shares with Human Immunodeficiency Virus (HIV). HSV-2 positive and HSV-2/HIV co-infected persons have a higher risk of contracting HIV infection [14–16], and of transmitting HIV [17, 18], respectively. The estimated proportion of HIV infections attributable to HSV-2 in areas with a high HSV-2 prevalence such as sub-Saharan Africa is approximately 25% [19]. Therefore, controlling HSV-2 could have a substantial population-level impact on HIV incidence in sub-Saharan Africa.

HSV-2 vaccines have gained more focus after the recent failure of HSV-2 suppression therapy to limit HIV spread in three randomized-controlled trials [20–22]. An ideal HSV-2 prophylactic vaccine would induce sterilizing immunity and prevent HSV-2 acquisition in susceptible populations. Meanwhile, imperfect [23] prophylactic HSV-2 vaccines could partially reduce HSV-2 acquisition in vaccinees, and/or partially reduce infectivity of those who get infected after vaccination, by either reducing their shedding frequency or viral load during shedding episodes. Because the effectiveness of a licensed vaccine is not known, mathematical modeling can determine the population-level impact of various combinations of protection regarding three biologic aspects of disease: susceptibility, shedding frequency, and infectivity while shedding.

Two prophylactic recombinant vaccines have completed phase III clinical trials and achieved limited success in protecting against HSV-2 acquisition [24–26]. A third vaccine that uses the full-length of gD with bupivacaine recently underwent successful testing in a safety and immunogenicity trial [27].

Because the current HSV-2 strategies target reduction in shedding as a primary outcome along with the classical target of susceptibility reduction [26, 28], the results of future clinical trials of vaccines will provide vaccine efficacies in terms of reduction in susceptibility and shedding frequency. These efficacies are obtained for individuals during the short period of the clinical trial. Therefore, the criteria for a favorable vaccine at the population level will not be directly obtained from these trials.

Our goal in this study was to estimate the population-level impacts of prophylactic HSV-2 vaccines using mathematical modeling. We introduced a model for HSV-2 in which the different aspects of prophylactic HSV-2 vaccines were parameterized to study their effects. While previous HSV-2 models [29, 30] studied population-level impact of HSV-2 vaccines in the United States, we estimated the impact of vaccination at the population level in a representative setting of hyperendemic HIV and HSV-2 epidemic in sub-Saharan Africa (Kisumu, Kenya). The impact of vaccination was estimated in terms of impact on prevalence, incidence, and infections averted per vaccination procedure.

We constructed a deterministic compartmental model calibrated to describe HSV-2 transmission in presence of vaccination in different populations but focused most of our analyses on a representative sub-Saharan African population (Kisumu, Kenya). The Supplementary Information Appendix contains the details of the model and its parameterization. The model stratifies the population into compartments according to vaccination status (vaccinated or unvaccinated), sexual risk group, and stage of HSV-2 infection using eight coupled nonlinear ordinary differential equations for each risk group of the four risk groups in the model. HSV-2 pathogenesis is represented by three stages: primary, latent (*no shedding*), and reactivated (*shedding*) stages. HSV-2 is of a chronic nature, therefore the latent and reactivated stages cycle through the entire life of the infected. The shedding frequency is assumed to be at 14% of each cycle [31]. The baseline transition rates of progression from primary to latent, latent to reactivated, and reactivated to latent are derived from the duration of each stage and the shedding frequency and they are 18.3, 4.7, and 28.6 per year, respectively. Baseline transmission probabilities per coital act per HSV-2 primary, latent, and reactivated stages are 0.01, 0.00, and 0.01, respectively[19]. We considered three possible efficacies for a prophylactic HSV-2 vaccine [23]: reducing susceptibility to infection (*VE _{S}*), and for those who get infected after the time of vaccination, reducing infectivity

Prophylactic-vaccine efficacies expected to be an output of vaccine randomized controlled trials [^{1}, ^{2}].

We quantified the effect that variability in *VE _{S}*,

Our summary measures are appropriate tools for estimating the long-term effect of a partially efficacious vaccine. To derive each summary measure analytically, we simplified our mathematical model for a population with uniform risk behavior. In the quantitative predictions presented below, for each vaccine efficacy scenario, we assumed universal adolescent vaccination (*f* =100%). Although it has never been proven that risk behavior compensation could accompany HSV-2 vaccination, for completeness we assumed a modest risk behavior compensation of *r* =10% for those vaccinated relative to baseline risk behavior. Other assumptions included a uniform average sexual-risk of two partners per year, and life-long protection upon vaccination.

To measure the short-term impact of a vaccine in a high prevalence region, we next presented a more detailed mathematical model that included heterogeneous risk behavior. This version of the model was fitted to Kisumu’s prevalence data. We chose the parameter values of the model according to the best available empirical evidence of the biology and epidemiology of HSV-2 infection. In particular, recently established detailed empirical data about the pattern of HSV-2 reactivation in its clinical and subclinical form [34], played a central role in our assumptions. The behavioral parameters in the model are informed by the measurements of the Four City study [35–37]. The model’s assumptions are listed in Table 2 along with their references.

Although there are substantial variations in the rate and pattern of HSV-2 reactivations [34, 38, 39], the critical parameter is the shedding frequency irrespective of whether the pattern is that of short but frequent reactivations or long but less frequent ones [19]; because by assumption the infectious state is manifested by shedding the virus and irrespective of the pattern of shedding. The assumption that all shedding is associated with possible transmission has not been validated, however. It is possible that only shedding above a certain quantitative threshold (such as 1000 HSV copies DNA/mL) commonly leads to transmission. A vaccine may also decrease infectivity of individual virions irrespective of their number due to increased immune surveillance in the genital tract. Vaccine efficacy of decreasing transmission during shedding *VE _{I}* accounts for both of the above possibilities.

Increasing any of the vaccine efficacies of reducing susceptibility (*VE _{S}*), shedding frequency (

A set of mixed scenarios for the impact of HSV-2 vaccination. The vaccine utility (Φ), the vaccinee infection fitness (Ψ), and the basic reproduction number (*R*_{0}_{V}) for a scenario versus (**A**) vaccine efficacy of reducing susceptibility to **...**

Figure 1 A displays that for a vaccine with a limited efficacy of reducing shedding frequency of *VE _{P}* =10% and no efficacy in reducing infectivity i.e.

However, as shown in Figure 1B, if *VE _{I}* =0% as in Figure 1A, an increase in

In contrast to Figure 1A and B, Figure 1C and D show how Ψ decreases steadily by increasing *VE _{P}* at two different values of

However, our predictions show that a vaccine with efficacy of reducing shedding frequency as high as 75% combined with efficacy of reducing susceptibility as low as 30% would be definitely and substantially beneficial in a population with an average of two sexual partners per year. Even though such an imperfect vaccine would not stop new HSV-2 infections among the vaccinated because of its low efficacy of reducing susceptibility, it still would effectively impact the dynamics of disease transmission. Moreover, it would render the number of secondary infections produced by infected and vaccinated individuals to one-quarter of the number produced by those infected and unvaccinated. The moderate risk compensation assumed here at 10% will not undermine the utility of such vaccine.

We next considered the epidemiology of intervention using vaccines in Kisumu, Kenya over a period of 10 years starting in 2010. We explored two schedules of vaccination: universal vaccination of adolescents as they enter sexual activity and mass vaccination of the sexually active population achieved within a year. We assumed vaccination using a vaccine with efficacy of reducing susceptibility to HSV-2 of *VE _{S}* =30%, efficacy of reducing HSV-2 shedding of

On the other hand, mass vaccination of all susceptible persons aged 15 to 49 by the year 2020 would reduce HSV-2 prevalence, incidence, and incidence rate by 7%, 30% and 35%, respectively. A total of 8430 HSV-2 infections would be averted by 2020 in Kisumu. Figure 2A and B displays how the impact of adolescent vaccination on prevalence and incidence rate would be less than mass vaccination and would take longer to accrue due to the delay time in achieving higher vaccination coverage. As shown in Figure 2A, although the impact of either schedule of vaccination on prevalence increases over time, the effect is initially modest. Equilibrium values of prevalence, incidence, and incidence rate would be achieved beyond year 2050 and would represent a percentage decrease of 69%, 69%, and 82%, with respect to baseline values, respectively. This delay is due to the lifelong nature of HSV-2 infection where the impact on prevalence will not be substantial until the already infected population ages and leaves the sexually active population. An additional cause of the delay is that the beneficial effects of *VE _{P}* and

Impacts of adolescence and mass vaccine interventions in Kisumu, Kenya administered in 2010 using a vaccine with efficacies of *VE*_{S} =30%, *VE*_{P} =75%, and *VE*_{I} =0. (**A**) Time series of prevalence values. The source of population survey data is the Four-City **...**

Furthermore, we investigated the ten-year impact of mass vaccination intervention in 2010 on HSV-2 excess prevalence (prevalence post-intervention subtracted from prevalence pre-intervention) and computed the number of vaccinated per infection averted in populations at various levels of total HSV-2 prevalence preserving the hierarchy of sexual risk of Kisumu’s settings (Figure 3). The excess prevalence is large when baseline prevalence in the absence of vaccination is high; the number of vaccinated per infection averted increases when HSV-2 prevalence in the absence of vaccination is lower. Eighteen vaccination procedures are needed per infection averted at high HSV-2 prevalence of 52%, projected for Kisumu, Kenya in 2010 which is representative of a large part of sub-Sharan Africa. This is compared to 64 vaccination procedures per infection averted for the United States at HSV-2 prevalence of 17%.

Impact of mass vaccination in diverse HSV-2 settings having the same hierarchy of sexual risk as in Kisumu, Kenya. (**A**) Number of vaccination procedures needed per each HSV-2 infection averted at varying baseline HSV-2 prevalence levels before vaccine **...**

We investigated the synergy between the vaccine efficacies of reducing shedding frequency and reducing susceptibility over time. The definition of synergy is delineated in the Supplementary Information Appendix. We found that (not shown) the effects of the two efficacies *VE _{S}* and

Finally, we performed sensitivity and uncertainty analyses to assess the robustness and sensitivity of our short and long-term predictions to uncertainty in the vaccine efficacies, sexual behavior parameters and risk group structure, HSV-2 progression parameters and risk compensation behaviors (Supplementary Information Appendix). We found that our short–term predictions for the impact of vaccine intervention by 2020 in terms of excess prevalence, relative reduction in incidence, and excess incidence rate are largely invariable to the assumed variations in the vaccine efficacies of reducing infectivity and shedding frequency, or behavioral and HSV-2 progression parameters. However, the predicted excess prevalence and incidence rate as well as the reduction in incidence show substantial variability in the short-term to the assumed variation in the vaccine efficacy of reducing susceptibility. This is expected as in the short-term it is mainly *VE _{S}* that is driving the impact of the vaccine.

Over the long-term, substantial sensitivity in our predictions are observed with respect to the assumed variations in the vaccine efficacy of reducing shedding frequency and in the shedding frequency itself, respectively. The long-term sensitivity results attest to the role of *VE _{P}* and shedding frequency in determining the course of HSV-2 transmission in presence of vaccination over a time horizon of few decades.

Our approach enables prediction of the potential population impact of vaccines immediately after clinical trial results are available. In the case of HSV-2, a vaccine candidate’s efficacy measures are likely to become available after a clinical trial: vaccine efficacy of reducing susceptibility (*VE _{S}*) is often the primary outcome measure of most vaccine trials; but because current HSV-2 strategies also target reduction in shedding [26, 28], it is now standard practice to measure the effect of all HSV-2 interventions on shedding frequency and therefore a detailed assessment of vaccine efficacy of reducing shedding frequency (

Our results underscore the relative impact of each of the vaccine efficacies at the population level, which is an important aspect of studying any imperfect vaccine. While the impact of *VE _{S}* at the population-level is immediate, the effects of

Our study has several limitations. First, it does not address heterogeneity in shedding frequency in the general population. Ranges of shedding frequency among HSV-2 infected persons are from 0% – 78% [40]. In addition, there is evidence that frequent shedders may serve as “super spreaders” irrespective of sexual risk behavior [41]. Therefore, the effect of high *VE _{P}* in this group would decrease the absolute amount of shedding more substantially than in infrequent shedding groups. Future mathematical models of vaccine efficacy would benefit from independent stratification of sexual risk behavior and shedding frequency into sub-groups. In addition, a true quantitative surrogate measure for transmission risk has not been identified as of yet. We account for the possibility that low-copy shedding may not be associated with transmission risk in our sensitivity analysis where we decrease shedding frequency, and also by incorporating

In summary, if HSV-2 vaccines that are currently under development have limited efficacy against HSV-2 acquisition, but have substantial efficacy of reducing shedding frequency or infectivity, then such vaccines are likely to have a high impact on HSV-2 incidence and prevalence over several decades, and will have a more immediate strong effect on HSV-2 incidence, particularly in high prevalence populations. Conversely, a vaccine that has a modest effect on acquisition but no effect on viral shedding is unlikely to be as effective. It is therefore imperative, that all future vaccine studies evaluate the effect that a vaccine has on genital viral shedding.

Mathematical modeling is used to derive summary measures for the utility of HSV-2 vaccination and to assess the epidemiological impact of vaccination.

RA and LJA are grateful for the Fred Hutchinson Cancer Research Center for supporting this work. LJA is grateful for the Qatar National Research Fund for supporting this work.

The HSV-2 basic reproduction number (*R*_{0}) for a population with no vaccination (*f* =0) is given by

(A.1)

where *t _{i}* is the transmission probabilities per partnership from HSV-2 infected individuals in HSV-2 stage

The HSV-2 basic reproduction number in a partially vaccinated population (*R*_{0}* _{V}*) is given by

(A.2)

where *VE _{S}*,

The vaccine utility (Φ) is defined by relative reduction in the basic reproduction number due to vaccination [32]: and is given by:

(A.3)

The vaccinee infection fitness (Ψ) is equal to the ratio of the number of secondary infections caused by an infected vaccinated individual (*R _{IV}*) to the number of secondary infections caused by an infected unvaccinated individual (

(A.4)

*Vaccine utility* was classified to *definitely beneficial* (deduced by Φ > 0 [33]) if it reduces endemic equilibrium values for prevalence, incidence (absolute number of incident infection per year), and incidence rate (number of incident infections per susceptible individual per year) compared to values without vaccination. The vaccine is considered *partially beneficial* (Φ =0) if at least one but not all of these values were reduced upon achieving equilibrium after vaccination and *perverse* (Φ <0) if none of these equilibrium values were reduced after vaccination. It is desirable for vaccines to have Φ >0, Ψ <1, and *R*_{0}* _{V}* <1.

Supplementary Information Appendix: Technical details of model description and sensitivity analysis.

1. Obasi A, Mosha F, Quigley M, et al. Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. J Infect Dis. 1999;179:16–24. [PubMed]

2. Wagner HU, Van Dyck E, Roggen E, et al. Seroprevalence and incidence of sexually transmitted diseases in a rural Ugandan population. Int J STD AIDS. 1994;5:332–337. [PubMed]

3. Kamali A, Nunn AJ, Mulder DW, et al. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. Sex Transm Infect. 1999;75:98–102. [PMC free article] [PubMed]

4. Gwanzura L, McFarland W, Alexander D, et al. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. J Infect Dis. 1998;177:481–484. [PubMed]

5. Rakwar J, Lavreys L, Thompson ML, et al. Cofactors for the acquisition of HIV-1 among heterosexual men: prospective cohort study of trucking company workers in Kenya. Aids. 1999;13:607–614. [PubMed]

6. Langeland N, Haarr L, Mhalu F. Prevalence of HSV-2 antibodies among STD clinic patients in Tanzania. Int J STD AIDS. 1998;9:104–107. [PubMed]

7. Dada AJ, Ajayi AO, Diamondstone L, et al. A serosurvey of Haemophilus ducreyi, syphilis, and herpes simplex virus type 2 and their association with human immunodeficiency virus among female sex workers in Lagos, Nigeria. Sex Transm Dis. 1998;25:237–242. [PubMed]

8. Chen CY, Ballard RC, Beck-Sague CM, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis. 2000;27:21–29. [PubMed]

9. Buvé A, Carael M, Hayes RJ, et al. Multicentre study on factors determining differences in rate of spread of HIV in sub-Saharan Africa: methods and prevalence of HIV infection. Aids. 2001;15(Suppl 4):S5–14. [PubMed]

10. Slomka MJ, Ashley RL, Cowan FM, et al. Monoclonal antibody blocking tests for the detection of HSV-1- and HSV-2-specific humoral responses: comparison with western blot assay. J Virol Methods. 1995;55:27–35. [PubMed]

11. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes. 2004;11(Suppl 1):24A–35A. [PubMed]

12. Celum C, Levine R, Weaver M, et al. Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ. 2004;82:447–453. [PubMed]

13. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008;86:805–812. A. [PubMed]

14. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids. 2006;20:73–83. [PubMed]

15. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2002;185:45–52. [PubMed]

16. Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV incidence. Aids. 2009;23:1595–1598. [PubMed]

17. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149–1153. [PubMed]

18. Latif AS, Katzenstein DA, Bassett MT, et al. Genital ulcers and transmission of HIV among couples in Zimbabwe. Aids. 1989;3:519–523. [PubMed]

19. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE. 2008;3:e2230. [PMC free article] [PubMed]

20. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358:1560–1571. [PMC free article] [PubMed]

21. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2109–2119. [PMC free article] [PubMed]

22. Hagerty C, Guiden M. Health Sciences/University of Washington Medicine news and community relations. Seattle, Washington, USA: 2009. Herpes medication does not reduce risk of HIV transmission from individuals with HIV and genital herpes but demonstrates modest reduction in HIV disease progression and leads to new important insights about HIV transmission, UW-led international study finds.

23. Halloran ME, Struchiner CJ, Longini IM., Jr Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol. 1997;146:789–803. [PubMed]

24. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Jama. 1999;282:331–340. [PubMed]

25. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652–1661. [PubMed]

26. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes. 2004;11(Suppl 3):161A–169A. [PubMed]

27. Cattamanchi A, Posavad CM, Wald A, et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol. 2008;15:1638–1643. [PMC free article] [PubMed]

28. HerpeVac Trial for Young Women. 2009. http://clinicaltrials.gov/ct2/show/NCT00057330.

29. Blower S. Modelling the genital herpes epidemic. Herpes. 2004;11(Suppl 3):138A–146A. [PubMed]

30. Schwartz EJ, Blower S. Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines. J Infect Dis. 2005;191:1734–1746. [PubMed]

31. Stamm WE, Handsfield HH, Rompalo AM, et al. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. Jama. 1988;260:1429–1433. [PubMed]

32. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc Biol Sci. 1993;253:9–13. [PubMed]

33. Abu-Raddad LJ, Boily MC, Self S, et al. Analytic insights into the population level impact of imperfect prophylactic HIV vaccines. J Acquir Immune Defic Syndr. 2007;45:454–467. [PubMed]

34. Mark KE, Corey L, Meng TC, et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis. 2007;195:1324–1331. [PubMed]

35. Ferry B, Carael M, Buvé A, et al. Comparison of key parameters of sexual behaviour in four African urban populations with different levels of HIV infection. Aids. 2001;15(Suppl 4):S41–50. [PubMed]

36. Lagarde E, Auvert B, Carael M, et al. Concurrent sexual partnerships and HIV prevalence in five urban communities of sub-Saharan Africa. Aids. 2001;15:877–884. [PubMed]

37. Morison L, Weiss HA, Buvé A, et al. Commercial sex and the spread of HIV in four cities in sub-Saharan Africa. Aids. 2001;15(Suppl 4):S61–69. [PubMed]

38. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis. 2008;198:1141–1149. [PMC free article] [PubMed]

39. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994;121:847–854. [PubMed]

40. Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest. 1997;99:1092–1097. [PMC free article] [PubMed]

41. Blower S, Wald A, Gershengorn H, et al. Targeting virological core groups: a new paradigm for controlling herpes simplex virus type 2 epidemics. J Infect Dis. 2004;190:1610–1617. [PubMed]

42. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. Jama. 2001;285:3100–3106. [PubMed]

43. Wald A, Krantz E, Selke S, et al. Knowledge of partners’ genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis. 2006;194:42–52. [PubMed]

44. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403–1409. [PubMed]

45. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science. 2006;314:1603–1606. [PubMed]

PubMed Central Canada is a service of the Canadian Institutes of Health Research (CIHR) working in partnership with the National Research Council's Canada Institute for Scientific and Technical Information in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine(NCBI/NLM). It includes content provided to the PubMed Central International archive by participating publishers. |